Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRX003 Lotion in Netherton Syndrome
NCT05789056Phase 3Recruiting
- Sponsor
- Quoin Pharmaceuticals Ltd.
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of QRX003 in Netherton syndrome (NS) (2 arms), sponsored by Quoin Pharmaceuticals Ltd. Primary endpoints: Investigator's Global Assessment 1-point reduction at 16 weeks, Investigator's Global Assessment 2-point reduction at 16 weeks and 6 more. Started Mar 2023; status: recruiting.
02
Drugs
QRX003
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT05789056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789056.